Effect of rosuvastatin on serum levels of vaspin and visfatin in patients with CAD

Abstract

METHODS: 80 patients who underwent coronary angiography due to symptoms of stable angina were enrolled in the study. 40 patients received Rosuvastatin 20 mg/day was compared to another 40 patients, as a control group, who refused statin treatment and preferred lifestyle modifications intervention. Main outcome measure: Clinical parameters, lipid profile, troponin I, high-sensitivity C-reactive protein (hs-CRP), Vaspin and Visfatin levels were assayed at the beginning and after 3 months. CAD severity was assessed by the Gensini score. RESULTS:Rosuvastatin administration considerably ameliorated most lipid parameters. Moreover, a significant increase of Vaspin and decrease of Visfatin concentrations (p<0.001) after Rosuvastatin treatment were observed (from 2.81 ± 0.74 ng/ml to 4.26 ± 0.76 ng/ml, from 4.62 ± 0.76 to 3.13 ± 0.98 respectively). There was a negative correlation between Vaspin and the Gensini score and positive correlation between Visfatin and Gensini score (r=-0.18 and r=0.19, p=0.05, respectively). CONCLUSION:Rousvastatin treatment reduces serum visfatin and increase serum vaspin levels in CAD patients. Those effects of Rousvastatin are of clinical importance.

Serum Adropin and Vaspin Levels in Obese Rats with Polycystic Ovary Syndrome and After Metformin Treatment

“…Also, the present study found a significant positive correlation between vaspin and D-dimer levels in all groups. Experiments also indicated that vaspin could inhibit the release of many inflammatory markers in vascular smooth muscle cells and reduce FFA-induced apoptosis in endothelial cells [39].…”

The effect of hydrophilic statins on adiponectin, leptin, visfatin and vaspin levels in streptozocin-induced diabetic rats

“…It has been reported that administration of atorvastatin, a lipophilic statin, decreases visfatin serum levels in Type II diabetic patients (Kadoglou et al 2012). In humans, serum visfatin levels have been decreased with the treatment of rosuvastatin in diabetic patients (Werida et al 2018). Both pravastatin and rosuvastatin decreased the visfatin level, but only pravastatin improved the fasting glucose level and body weight in our study.…”